睿知中国医院研究地图
候选清单

即将招募乳腺癌早期I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由青岛大学附属医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方青岛大学附属医院Affiliated Hospital of Qingdao University青岛医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05505812,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 75 岁;性别:仅女性

    登记记录的入选字段

  2. Histologically or cytological diagnosed as advanced breast cancer;

    入选标准第 3 条

  3. Test subjects must have recovered from all prior therapy-related toxicities to ≤Grade 1 according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0; except for alopecia (tumor resection);

    入选标准第 15 条

    Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent, and continue within 180 days after the completion of treatment;

    入选标准第 16 条

    Current or prior use of anticancer therapy: a.) chemotherapy, immune checkpoint inhibitor, other investigational therapy drug or local treatment for target lesions within the past 4 weeks; b.) chinese patent medicine with anti-tumor indications, or systemic therapy with immunomodulatory drugs (including thymosin, interferon, drugs targeting) within the past 2 weeks; c.) targeted drug therapy within the past 4 weeks or 5 half-lives, whichever is shorter;

    排除标准第 11 条

    Test subjects who have had another primary malignancy within the previous 5 years, excluding basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after radical resection;

    排除标准第 21 条

  4. ECOG score 0-2;

    入选标准第 7 条

  5. Absolute count of neutrophil ≥1.5×10\^9/L; Platelet count ≥90×10\^9/L; Hemoglobin ≥ 90g/L (None blood transfusion or erythropoietin treatment within 14 days);

    入选标准第 10 条

    AST, ALT≤2.5×ULN (subjects with liver metastasis ≤5×ULN); Totol bilirubin ≤1.5×ULN;

    入选标准第 11 条

    Serum creatinine ≤1.5×ULN, or estimated creatinine clearance (CrCl)≥45 mL/min (Cockcroft-Gault formula);

    入选标准第 12 条

    Activated partial thromboplastin time (APTT) ≤1.5×ULN, while international no○rmalized ratio (INR) or prothrombin (PT) ≤1.5×ULN;

    入选标准第 13 条

  6. Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive;

    排除标准第 13 条

  7. Females in pregnancy or lactation;

    排除标准第 22 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05505812,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. To be eligible for the study, patients must meet ALL of the following criteria prior to participation:
  2. Age: 18 years to 75 years at the time of consent (Female);
  3. Histologically or cytological diagnosed as advanced breast cancer;
  4. Test subjects have failed first-line standard treatment regimens, and there are no available effective treatment regimens option or refuses to accept further treatment;
  5. At least one resectable lesion that has not received radiotherapy or other local therapy within 28 days, and of aminimum 1cm∧3 resection;or resectable lesions capable of producing sufficient TIL;
  6. At least one measurable target lesion, as defined by RECIST v1.1,that has not received radiotherapy or other local therapy unless these therapies occurred 28 days ago and target lesion shows significant progression;
  7. ECOG score 0-2;
  8. Expected life-span more than 3 months;
  9. Adequate organ and bone marrow function:
  10. Absolute count of neutrophil ≥1.5×10\^9/L; Platelet count ≥90×10\^9/L; Hemoglobin ≥ 90g/L (None blood transfusion or erythropoietin treatment within 14 days);
  11. AST, ALT≤2.5×ULN (subjects with liver metastasis ≤5×ULN); Totol bilirubin ≤1.5×ULN;
  12. Serum creatinine ≤1.5×ULN, or estimated creatinine clearance (CrCl)≥45 mL/min (Cockcroft-Gault formula);
  13. Activated partial thromboplastin time (APTT) ≤1.5×ULN, while international no○rmalized ratio (INR) or prothrombin (PT) ≤1.5×ULN;
  14. LVEF ≥ 50%, none symptomatic or poorly controlled arrhythmias;
  15. Test subjects must have recovered from all prior therapy-related toxicities to ≤Grade 1 according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0; except for alopecia (tumor resection);
  16. Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent, and continue within 180 days after the completion of treatment;
  17. Be able to understand and sign the informed consent document.

排除标准:Exclusion Criteria:

  1. Patients with any of the following criteria will not be allowed to participation:
  2. Test subjects who have a history of hypersensitivity to any component or excipient of HS-IT101 or other study drugs (cyclophosphamide, fludarabine and recombinant human interleukin-2);
  3. Test subjects have any uncontrollable clinical problems (including but not limited):
  4. hypertension poorly controlled by medication (blood pressure ≥150/90mmHg at rest after taking medication);
  5. poorly controlled diabetes;
  6. cardiac disease (New York Heart Association class Ⅲ/Ⅳ congestive heart failure or heart block);
  7. Test subjects who have active major medical illnesse(es) of the cardiovascular (within 6 months prior to enrollment), including deep vein thrombosis or pulmonary embolism; myocardial infarction; severe or unstable arrhythmia or angina pectoris; percutaneous coronary intervention, acute coronary syndrome, coronary artery bypass grafting; cerebrovascular accident, transient cerebral ischemia Seizures, cerebral embolism;
  8. Active autoimmune diseases or recipients of organ transplants that require systemic treatment during the study period, or a history of such diseases within the past 2 years;
  9. Prior used any immunosuppressive medications, such as corticosteroids (within 14 days prior to enrollment); physiological doses of glucocorticoids (≤10 mg/day prednisone or equivalent) are permitted, as well as inhaled, intranasal, or topical corticosteroids;
  10. Test subjects with symptomatic and/or untreated brain metastases;
  11. Current or prior use of anticancer therapy: a.) chemotherapy, immune checkpoint inhibitor, other investigational therapy drug or local treatment for target lesions within the past 4 weeks; b.) chinese patent medicine with anti-tumor indications, or systemic therapy with immunomodulatory drugs (including thymosin, interferon, drugs targeting) within the past 2 weeks; c.) targeted drug therapy within the past 4 weeks or 5 half-lives, whichever is shorter;
  12. Presence of acute or chronic infection:
  13. Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive;
  14. Active TB infection;
  15. Active bacterial or fungal infection requiring systemic treatment;
  16. HBsAg and/or HBeAg positive;
  17. Hepatitis C patients;
  18. Treponema pallidum antibodies positive;
  19. Vaccinated with the new coronavirus vaccine within 14 days propr to screening, or who have received a live vaccine within 3 months, or who plan to receive live vaccine during the trial;
  20. Major organs underwent surgery (excluding needle biopsy) or significant trauma within 4 weeks before screening;required elective surgery during the study;
  21. Test subjects who have had another primary malignancy within the previous 5 years, excluding basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after radical resection;
  22. Females in pregnancy or lactation;
  23. Test subjects have had SAE requiring blood product support occurred in previous chemotherapy, including but not limited to whole blood, red blood cells, platelets;
  24. Subject have mental illness, alcoholism, drug or substance abuse;or researchers considering the test subject as having other reasons inappropriate for the clinical study.

引自 ClinicalTrials.gov, NCT05505812, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05505812,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05505812